Black checkmark with a sparkle and a curved line underneath on a white background.
Company

RADNOSTIX INC

Ticker
INIS
Sector
Industry
Report date
November 16, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes market activity in agricultural commodities and unrelated industry developments; no direct recent news about Radnostix's business operations was identified.

Recent developments:
  • Hogs posted gains across the board on Friday [N1].
  • Wheat posted gains on Friday [N2].
  • Cattle rounded out the week with gains [N3].
  • Soybeans posted gains following export announcements [N4].
  • Johnson & Johnson announced acquisition of Ollin Biosciences in a $2.2 billion deal [N5].
  • MapLight moved toward Phase 3 schizophrenia trial with ongoing enrollment [N6].
  • Cosan S.A. reported Compass IPO, Raízen restructuring, and asset sales in its September 30, 2026 interim report [N7].
  • TOMI Environmental Solutions reported preliminary third quarter 2026 financial results [N8].
Overview

Radnostix Inc. manufactures and distributes a broad range of nuclear medicine calibration and reference standards, cobalt-60 products, theranostics products including FDA-approved generic sodium iodide I-131, and medical devices. The company operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. It serves customers in nuclear pharmacies, imaging clinics, research laboratories, and industrial applications across the U.S. and internationally. The company holds various regulatory licenses including FDA approvals and NRC licenses. Recent developments include an asset sale agreement for its Fluorine Products segment and ongoing product development in medical devices.

Executive summary

Radnostix Inc. is a U.S.-based company specializing in nuclear medicine calibration and reference standards, cobalt products, theranostics products including FDA-approved generic sodium iodide I-131, medical devices, and fluorine products. The company operates five reportable segments and distributes products domestically and internationally. Recent SEC filings disclose a net loss for Q3 2026 and ongoing FDA regulatory compliance activities including corrective actions following an Official Action Indicated and voluntary product recalls. The company has a current ratio below 1.0 as of September 30, 2026, indicating liquidity constraints. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for INIS

Bull case model:

The company's FDA-approved generic sodium iodide I-131 product offers a domestic alternative to foreign suppliers, potentially capturing market share in theranostics. Its unique licensing and compliance capabilities position it well in the growing radiopharmaceutical market. Expansion of medical device offerings and asset sales may provide additional revenue streams and operational focus. The company's broad geographic distribution and regulatory approvals support market penetration.

Bear case model:

The company faces regulatory risks including potential FDA enforcement actions related to manufacturing compliance and product recalls. Liquidity constraints indicated by a current ratio below 1.0 may impact operational flexibility. Competition in radiochemical and calibration markets is intense, with foreign and domestic players. Delays or failures in medical device development and commercialization could limit growth. The asset sale of the Fluorine Products segment may reduce diversification.

Moat:

Radnostix's competitive advantages include its FDA-approved generic sodium iodide I-131 product, unique NRC licensing status permitting handling of high energy and high activity radioisotopes, compliance with GMP standards, and experienced personnel. Its domestic manufacturing capabilities provide a competitive edge over foreign suppliers in cobalt-60 products. The company's broad product portfolio and strategic partnerships with OEMs in calibration and reference products further strengthen its market position.

Risks overview
Risks summary
Regulatory compliance and liquidity constraints represent the most significant risks to Radnostix's operational stability and growth potential.
Risks details:

• Regulatory Compliance Risk: The company is subject to FDA regulations and inspections. An Official Action Indicated in April 2025 led to corrective actions, but there remains risk of further FDA enforcement including warning letters or manufacturing holds [S2].
• Product Recall Risk: Two voluntary recalls occurred in early 2026 related to product quality issues, which could impact customer trust and regulatory standing [S2].
• Liquidity Risk: As of September 30, 2026, the company had a current ratio of 0.68 and cash ratio of 0.16, indicating potential liquidity constraints [S2].
• Market Competition Risk: The markets for radiochemicals and calibration products are highly competitive with both domestic and international suppliers [S2].
• Development and Commercialization Risk: Medical device products are in development stages; delays or failures in commercialization could affect future revenue [S2].

FINAL FORECAST FOR INIS

Final take one line
Radnostix Inc. operates a diversified nuclear medicine and radiopharmaceutical business with detailed regulatory compliance and financial disclosures, facing regulatory and liquidity risks.
Final take 12 to 24 month view

Business trends: The company is engaged in expanding its theranostics and medical device segments while divesting non-core fluorine assets, operating in a competitive and regulated nuclear medicine market.
Execution milestones: Completion of FDA corrective actions, commercialization of new medical devices, and closing of the fluorine assets sale are key milestones.
Key risks: Regulatory compliance challenges, product recall impacts, liquidity constraints, and competitive pressures in radiopharmaceutical markets.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Radnostix Inc. is a U.S.-based company incorporated in Texas with principal executive offices in Idaho Falls, Idaho [S1].
  • The company operates through five reportable segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products [S2].
  • Theranostics Products segment includes FDA-approved generic sodium iodide I-131 for treatment of hyperthyroidism and thyroid cancer, radiochemicals for clinical research, and cGMP Active Pharmaceutical Ingredient supply for third parties [S2].
  • Cobalt Products segment produces cobalt-60 products for medical, research, and industrial applications, including sealed sources for radiation therapy and recycling of expended cobalt-60 sources [S2].
  • Calibration & Reference Products segment manufactures sealed source calibration and reference standards used in nuclear pharmacies, imaging clinics, laboratories, and industrial settings; products include flood sources, dose calibrator sources, phantoms, and specialty packaging [S2].
  • Medical Devices segment sells third-party products and is developing proprietary devices including the EasyFill Iodine Encapsulation System and RadVent branded products; acquired assets from Lucerno Dynamics for Lara and Ellexa systems [S2].
  • Fluorine Products segment holds NRC licenses for a depleted uranium facility in New Mexico; the company entered an asset purchase agreement to sell these assets for $13.5 million [S2].
  • The company had FDA inspections resulting in an Official Action Indicated in April 2025 and implemented corrective actions with ongoing initiatives to strengthen its Quality Management System; voluntary recalls occurred in early 2026 with FDA knowledge and are awaiting formal closeout [S2].
  • As of September 30, 2026, the company reported cash and equivalents of $711,288, current assets of $2,987,092, current liabilities of $4,370,330, resulting in a current ratio of 0.68 and cash ratio of 0.16 [S2].
  • The company had a net loss of $842,242 for the three months ended September 30, 2026, with basic and diluted EPS of $0 [S2].
  • The Board of Directors consists of five members with significant expertise in nuclear medicine, radiopharmaceuticals, and financial management; key executives include CEO Shahe Bagerdjian and CFO W. Matthew Cox [S1].
  • The company distributes its products across all 50 U.S. states and internationally, targeting customers in nuclear medicine, clinical trials, and industrial applications [S2].
  • The company filed a Type II Drug Master File with the FDA in October 2026 for Sodium Iodide I-131 API to support customer regulatory submissions [S2].
  • Recent news coverage includes market activity in agricultural commodities and unrelated industry news; no direct recent news about Radnostix's business operations was identified [N1][N2][N3][N4][N5][N6][N7][N8].
  • The company changed its name from International Isotopes Inc. to Radnostix Inc. as of December 31, 2025 [S1].
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-30 | 10-K/A
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-16 | www.nasdaq.com | Hogs Post Gains Across the Board on Friday | https://www.nasdaq.com/articles/hogs-post-gains-across-board-friday
  • N2 | 2026-11-16 | www.nasdaq.com | Wheat Posts Friday Gains | https://www.nasdaq.com/articles/wheat-posts-friday-gains-0
  • N3 | 2026-11-16 | www.nasdaq.com | Cattle Rounding Out the Week with Gains | https://www.nasdaq.com/articles/cattle-rounding-out-week-gains-0
  • N4 | 2026-11-16 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
  • N5 | 2026-11-16 | www.nasdaq.com | Johnson & Johnson To Acquire Ollin Biosciences In $2.2 Bln Deal | https://www.nasdaq.com/articles/johnson-johnson-acquire-ollin-biosciences-22-bln-deal
  • N6 | 2026-11-16 | www.nasdaq.com | MapLight Moves Toward Phase 3 Schizophrenia Trial; VISTA Study Enrollment Continues | https://www.nasdaq.com/articles/maplight-moves-toward-phase-3-schizophrenia-trial-vista-study-enrollment-continues
  • N7 | 2026-11-16 | www.nasdaq.com | Cosan S.A. Reports Compass IPO, Raízen Restructuring, and Asset Sales in September 30, 2026 Interim Report | https://www.nasdaq.com/articles/cosan-sa-reports-compass-ipo-raizen-restructuring-and-asset-sales-september-30-2026
  • N8 | 2026-11-16 | www.nasdaq.com | TOMI Environmental Solutions, Inc. Reports Preliminary Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/tomi-environmental-solutions-inc-reports-preliminary-third-quarter-2026-financial-results
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine